drugset
drugset / Trial / NCT04517253

A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

NCT04517253 ↗

Phase 2/3 Terminated 10 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), STING-associated vasculopathy with onset during infancy (SAVI), and Aicardi-Goutières Syndrome (AGS).

Timeline

Start
2020-10-27
Primary completion
2023-04-04
Completion
2024-11-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 6 mg Oral
Subject Baricitinib Small molecule 8 mg Oral
Subject Baricitinib Small molecule 10 mg Oral
Subject Baricitinib Small molecule 12 mg Oral

Indications

Aicardi-Goutieres syndrome STING-associated vasculopathy with onset in infancy proteosome-associated autoinflammatory syndrome